Information Provided By:
Fly News Breaks for March 23, 2015
BIIB
Mar 23, 2015 | 08:38 EDT
Morgan Stanley raised Overweight rated Biogen's price target to $525 to reflect BIIB037 data. The firm views risk/reward as favorable into the next catalysts that include Tysabri for SPMS in mid-year 2015, Tysabri for stroke expected in Q4, and full anti-LINGO data in MS in 1H 2016.
News For BIIB From the Last 2 Days
There are no results for your query BIIB
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.